WHO ICTRP trial
Role of Escitalopram Add-on in schizophrenia having subsyndromal depressive…
CTRI/2018/01/011551 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2018/01/011551 |
|---|---|
| Public title | Role of Escitalopram Add-on in schizophrenia having subsyndromal depressive symptoms |
| Scientific title | A study of Escitalopram Add-on in patients with stable schizophrenia having subsyndromal depressive symptoms |
| Primary sponsor | Pooja Singh |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Post Marketing Surveillance |
| Countries | India |
| Conditions | Health Condition 1: null- STABLE SCHIZOPHRENIA |
| Interventions | Intervention1: escitalopram: escitalopram is an antidepressant Control Intervention1: Escitalopram and placebo: Escitalopram 10mg 1HS for 8 weeks Placebo 1 capsules 1HS for 8 weeks |
| Registration date | Jan 24, 2018 |
| Target size | 66 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: